| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KIN001-266 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.19 | 0.003 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | 0.089 | 0.004 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.18 | 0.004 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.099 | 0.004 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.097 | 0.004 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.15 | 0.004 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.005 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.098 | 0.005 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.1 | 0.006 |